However, the in vitro work of Zhou et al. using SW620 and our own unpublished work using breast cancer cells strongly suggests that simultaneous treatment of Factor VIIa alongside tissue factor is required to increase proliferation via PAR‐2.33 This evidence concerns the gene F3 and breast carcinoma.